Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|RG7112||RO5045337|RO-5045337||MDM2 Inhibitor 19||RG7112 (RO5045337) binds to the p53-binding region of MDM2 and inhibits MDM2-p53 interaction, resulting in activation of p53 signaling, and decreased tumor cell growth (PMID: 24900694, PMID: 23400593, PMID: 31493899).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||acute myeloid leukemia||not applicable||RG7112||Phase I||Actionable||In a Phase I clinical trial, RG7112 demonstrated clinical activity in acute myeloid leukemia, with complete response in 7% (2/30), complete response with incomplete platelet recovery in 3% (1/30), partial response in 7% (2/30), and stable disease in 30% (9/30) of patients (PMID: 26459177).||26459177|
|Unknown unknown||sarcoma||not applicable||RG7112||Phase I||Actionable||In a Phase I clinical trial, RG7112 demonstrated safety and preliminary efficacy, with evidence supporting p53 activation, in soft tissue sarcoma patients with MDM2 amplification (J Clin Oncol 30, 2012 (suppl; abstr e13600).||detail...|
|Unknown unknown||chronic leukemia||not applicable||RG7112||Phase I||Actionable||In a Phase I clinical trial, 5% (1/19) of chronic leukemia patients achieved partial response, and 79% (15/19) achieved stable disease following treatment with RG7112 (PMID: 26459177).||26459177|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|